Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel

被引：3
|
作者：
Park, Joon Oh
Kim, Seung Tae
Hong, Jung Yong
Kim, Seong-Jin
Park, Young Suk
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] GILO Fdn, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS632
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts)
    Bekaii-Saab, T.
    Starodub, A.
    El-Rayes, B.
    O'Neil, B.
    Shahda, S.
    Ciombor, K.
    Noonan, A.
    Hanna, W.
    Sehdev, A.
    Shaib, W.
    Mikhail, S.
    Neki, A.
    Oh, C.
    Li, Y. Z.
    Li, W.
    Borodyansky, L.
    Li, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries
    Hayasaki, Aoi
    Kishiwada, Masashi
    Murata, Yasuhiro
    Komatsubara, Haruna
    Nakagawa, Yuki
    Maeda, Koki
    Shinkai, Toru
    Noguchi, Daisuke
    Gyoten, Kazuyuki
    Fujii, Takehiro
    Iizawa, Yusuke
    Tanemura, Akihiro
    Kuriyama, Naohisa
    Sakurai, Hiroyuki
    Isaji, Shuji
    Mizuno, Shugo
    PANCREAS, 2021, 50 (08) : 1230 - 1235
  • [43] Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] Comparative eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent FOLFIRINOX (FIO) versus nab-paclitaxel plus gemcitabine (NG)
    Cheung, Winson Y.
    Renouf, Daniel John
    Lim, Howard John
    Peixoto, Renata D'Alpino
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Observational study of comparative effectiveness of nab-paclitaxel plus gemcitabine vs gemcitabine plus cisplatin or gemcitabine alone for the first-line treatment of metastatic pancreatic adenocarcinoma in the University Hospital Centre Zagreb
    Prejac, J.
    Gorsic, I.
    Vidovic, M.
    Golem, H.
    Kekez, D.
    Librenjak, N.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 46 - 46
  • [46] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Dean, Andrew
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Cutsem, Eric V.
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 202 - 203
  • [47] Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma
    Noel, M.
    Lowery, M.
    Ryan, D.
    Wolpin, B.
    Bullock, A.
    Britten, C.
    Jin, B.
    Ganguly, B. J.
    Taylor, C. T.
    Yin, D.
    Wunderlich, D. A.
    Gamelin, E. C.
    Linehan, D. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261
  • [49] Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Lu, Yun-Xin
    Bai, Bing
    Zhang, Yang
    Wang, Zhi-Qiang
    Liu, Yu
    Chen, Jian-Wen
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 659 - 659
  • [50] ARC-8: Phase 1/1b randomized study of quemliclustat plus gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.
    Wainberg, Zev A.
    Manji, Gulam Abbas
    Bahary, Nathan
    Ulahannan, Susanna Varkey
    Pant, Shubham
    Uboha, Nataliya Volodymyrivna
    Oberstein, Paul Eliezer
    Lu, Lawrence H.
    Scott, Jennifer R.
    Wu, Wilson
    Rhee, Joon
    Nuyten, Dimitry S. A.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 665 - 665
12345